Abstract 1021
Background
Induction chemotherapy (IC) often compromises the compliance of following chemoradiotherapy (CRT) in LA-SCCHN. In particular, impaired compliance of cisplatin (CDDP) during CRT negatively affects outcomes. Here, we aimed to assess the feasibility and efficacy of paclitaxel (PTX), carboplatin (CBDCA), and cetuximab (Cmab) as IC for unresectable LA-SCCHN.
Methods
Patients with biopsy-proven, unresectable LA-SCCHN were enrolled. IC consisted of CBDCA AUC = 1.5, PTX 80mg/m2 and Cmab with an initial dose of 400mg/m2 followed by 250mg/m2 administered weekly for 8 weeks. Following IC, CDDP (20mg/m2, 4 days x 3 cycles) and concurrent radiotherapy (70Gy/35fr) were started. Primary endpoint was the rate of CRT completion, defined by (1) completion of planned CDDP relative dose intensity (RDI) ≥ 80%, and (2) completion of radiotherapy within 2 weeks after planned completion date. PCE was planned to be deemed effective if the Bayesian posterior probability (PP) that the rate of CRT completion was > 65% exceeded 84%.
Results
35 patients were eligible and received study treatment. Cases were hypopharynx/oropharynx/larynx in 17/17/1 patients, all Stage IV (stage IVA: 24, stage IVB: 11). Of 35 patients, 34 (97%) completed IC and 32 received CRT (FAS). Of 32 FAS cases, the rate of CRT completion was 96.9%, and the study’s primary endpoint was therefore met (PP = 99.9% > 84%). Mean cumulative dose and RDI of CDDP in CRT was 232.5mg (160-240mg) and 100% (66.7-100%), respectively. Response rate was 88.6% in the IC phase and 93.8% in the CRT phase. 2-year rates of local progression, distant metastasis, event-free survival and overall survival were 34.9%, 16.7%, 55.1% and 83.5%, respectively. Main grade 3 toxicities included neutropenia (11%), skin rash (6%), and anemia (6%) in the IC phase; and oral mucositis (31%), neutropenia (13%), and radiation dermatitis (13%) in the CRT phase. No grade 4 toxicity or treatment-related death was seen.
Conclusions
PCE as IC was feasible, with promising efficacy and no effect on compliance of following CRT in unresectable LA-SCCHN. A Phase III comparison with CRT alone is warranted.
Clinical trial identification
UMIN000014430.
Legal entity responsible for the study
IC-PCE Study Executive Committee.
Funding
National Cancer Center Research and Development Fund (25-B-2).
Editorial Acknowledgement
Disclosure
K. Okami: Honoraria: Merck Serono Co, Ltd; Consulting or advisory role: Merck Serono Co, Ltd. S. Minami: Speakers’ bureau: Nihon Cochlear; Research funding: Taiho Pharmaceutical, Kyorin Pharmaceutical. S. Iwae: Research funding: Ono Pharmaceutical CO, Ltd, Otsuka Pharmaceutical CO, Ltd. S. Nomura: Employment: Asahi Kasei Pharma (Immediate Family Member). S. Okano: Honoraria: Merck Serono, Brystol-Myers Squibb, Ono Pharmaceutical Co, Nippon Kayaku Co. M. Tahara: Honoraria: Bristol-Myers Squibb, Ono Pharmaceutical CO, Ltd, Merck Serono Co, Ltd, Eisai Co, Ltd, AstraZeneca PLC. All other authors have declared no conflicts of interest.
Resources from the same session
4162 - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer
Presenter: Anu Moilanen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3747 - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.
Presenter: Roman Dubianski
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4688 - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.
Presenter: Pietro Paolo Vitiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
498 - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Presenter: Xiao Fu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3731 - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1215 - Cisplatin in NIPEC or HIPEC?
Presenter: Ivan Alvovsky
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2738 - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment
Presenter: MARIKO HIRAI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2190 - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis
Presenter: Priya Sriskandarajah
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4482 - Functional inhibition of TGF-_ in colorectal cancer cells and its interaction with AXL receptor
Presenter: Davide Ciardiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
624 - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma
Presenter: Hugo Arasanz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract